These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30829619)

  • 1. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
    Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
    J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
    Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
    Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
    Lang AE; Gill S; Patel NK; Lozano A; Nutt JG; Penn R; Brooks DJ; Hotton G; Moro E; Heywood P; Brodsky MA; Burchiel K; Kelly P; Dalvi A; Scott B; Stacy M; Turner D; Wooten VG; Elias WJ; Laws ER; Dhawan V; Stoessl AJ; Matcham J; Coffey RJ; Traub M
    Ann Neurol; 2006 Mar; 59(3):459-66. PubMed ID: 16429411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
    Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
    Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
    Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
    J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
    Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; Heywood P
    Nat Med; 2003 May; 9(5):589-95. PubMed ID: 12669033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.
    Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
    J Neurosurg; 2005 Feb; 102(2):216-22. PubMed ID: 15739547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDNF delivery for Parkinson's disease.
    Patel NK; Gill SS
    Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
    Nutt JG; Burchiel KJ; Comella CL; Jankovic J; Lang AE; Laws ER; Lozano AM; Penn RD; Simpson RK; Stacy M; Wooten GF;
    Neurology; 2003 Jan; 60(1):69-73. PubMed ID: 12525720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease.
    Tripathi RK; Goyal L; Singh S
    Curr Gene Ther; 2024; 24(4):278-291. PubMed ID: 38310455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
    Yasuhara T; Shingo T; Date I
    Acta Med Okayama; 2007 Apr; 61(2):51-6. PubMed ID: 17471304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the role of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
    Kakoty V; Sarathlal KC; Kaur P; Wadhwa P; Vishwas S; Khan FR; Alhazmi AYM; Almasoudi HH; Gupta G; Chellappan DK; Paudel KR; Kumar D; Dua K; Singh SK
    Neurol Sci; 2024 Apr; 45(4):1409-1418. PubMed ID: 38082050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
    Patel NK; Bunnage M; Plaha P; Svendsen CN; Heywood P; Gill SS
    Ann Neurol; 2005 Feb; 57(2):298-302. PubMed ID: 15668979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.